Systemic Lupus Erythematosus | Disease Landscape & Forecast | G7 | 2023
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be highly variable between patients. GlaxoSmithKline’s Benlysta (2011) was the first drug to launch for SLE in the G7 in more than 50 years; however, its modest efficacy is a deterrent to uptake. Of note, AstraZeneca’s Saphnelo (anifrolumab) was approved in 2021-2022 throughout the G7 for nonrenal SLE. Additionally, GlaxoSmithKline’s Benlysta and Aurinia’s Lupkynis (voclosporin) have been approved for adult patients with active lupus nephritis (LN). Several therapies in development for moderate to severe SLE without active renal disease and/or LN (i.e., anifrolumab, dapirolizumab pegol, voclosporin, obinutuzumab, secukinumab, BIIB059 (litifilimab), ianalumab, and telitacicept) are expected to fulfill the high unmet need associated with this condition. In this report, we provide detailed analyses of current medical practice, key unmet needs, and new developments in the SLE space, along with an analysis of the opportunities and obstacles facing emerging agents.
Questions answered
- How large is the treatable SLE population, and how will diagnosis / drug-treatment rates change over time?
- What is the current state of SLE treatment? What are the most important drugs for the treatment of patients without active renal disease and LN, and why? What are interviewed experts’ insights into current treatment options? What are the key unmet needs in SLE?
- What are KOLs’ perception of key emerging therapies, and where do they see these agents fitting into the treatment algorithm? What sales / uptake could these agents secure in SLE? What therapies of note are progressing in earlier phases?
- What are the drivers and constraints in the SLE market, and how will the market evolve over the forecast period?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan
Primary research: Approximately 28 country-specific interviews with rheumatologists and nephrologists
Epidemiology: Diagnosed prevalence of SLE by country and subpopulation (nonrenal SLE and LN)
Population segments in the market forecast: Total population, nonrenal SLE population, and renal SLE (LN) population
Emerging therapies: Phase 2: 15 drugs; Phase 3: 9 drugs
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
